Bioventus Inc.
BVSNASDAQHealthcare● Active
$9.02
$-0.02(-0.19%)
Market Cap$611270313
P/E Ratio—
52W High$11.249
52W Low$5.81
Bioventus Inc. (BVS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BVS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.57B | $0.57B | $0.51B | $0.51B | $0.43B |
| Cost of Revenue | $0.19B | $0.19B | $0.18B | $0.18B | $0.13B |
| Gross Profit | $0.38B | $0.39B | $0.33B | $0.33B | $0.30B |
| Gross Margin %(computed) | 67.32% | 67.72% | 64.06% | 64.65% | 70.25% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.01B | $0.02B | $0.02B |
| G&A Expenses | $0.00B | $0.32B | $0.30B | $0.33B | $0.00B |
| Total Operating Expenses | $0.32B | $0.40B | $0.41B | $0.50B | $0.29B |
| Operating Income | $0.06B | ($0.01B) | ($0.08B) | ($0.17B) | $0.01B |
| Operating Margin %(computed) | 10.31% | -2.09% | -15.95% | -32.66% | 2.80% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.04B | $0.04B | $0.01B | $0.00B |
| Income Before Tax | $0.03B | ($0.05B) | ($0.12B) | ($0.19B) | $0.01B |
| Income Tax Expense | ($0.00B) | ($0.01B) | $0.00B | ($0.04B) | ($0.00B) |
| Net Income | $0.02B | ($0.03B) | ($0.16B) | ($0.16B) | $0.02B |
| Net Margin %(computed) | 4.00% | -5.85% | -30.49% | -30.99% | 4.50% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.34 | $-0.52 | $-2.49 | $-2.59 | $-0.15 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.06B | 0.06B | 0.05B |
| EBITDA | $0.11B | $0.04B | ($0.02B) | ($0.12B) | $0.05B |
| EBITDA Margin %(computed) | 18.58% | 6.84% | -4.50% | -23.75% | 10.55% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Bioventus Inc. data
About Bioventus Inc. (BVS) Income Statement
Bioventus Inc. (BVS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BVS reported revenue of $0.57B, gross profit of $0.38B (gross margin 67.32%), and net income of $0.02B — a net profit margin of 4.00%.
Frequently asked questions
BVS · 4 questionsBioventus Inc. (BVS) reported revenue of $0.57B for 2025, down 0.9% year-over-year.
BVS revenueBVS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08